



ImpediMed Limited  
1/50 Parker Court,  
Pinkenba, QLD, 4008  
Australia

E: [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)

W: [impedimed.com](http://impedimed.com)

8 October 2024

Companies Announcements Office  
Australian Securities Exchange

**National Accreditation Program for Breast Centers (NABPC) Optimal Resources for Breast Care Standards updated to recommend use of Lymphoedema Prevention Programs, including Bioimpedance Spectroscopy**

ImpediMed Limited (ASX: IPD) today reports that the U.S. National Accreditation Program for Breast Centers (NABPC) released an update of the Optimal Resources for Breast Care Standards which, for the first time, includes bioimpedance spectroscopy (BIS).

The NAPBC is a quality program of the American College of Surgeons. NAPBC-accredited programs must understand, implement and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care, as written and defined by the NAPBC<sup>1</sup>. Accredited centers must monitor compliance for standards and prepare for onsite review to maintain accreditation every three years.

The updated NABPC Standard Section 5.15 Survivorship notes that NABPC-accredited programs must use evidence-based guidelines to manage survivorship. Examples of evidence-based guidelines include, but are not limited to, the following:

- Referral to outpatient rehabilitation for evaluation and treatment of lymphoedema, as needed;
- Use of a lymphoedema prevention program, including regular symptom assessment and clinical evaluation using objective measurements of lymphoedema, such as bioimpedance spectroscopy.

ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphoedema. The Company's SOZO<sup>®</sup> Digital Health Platform is broadly accepted and recognised for effective and accurate screening of lymphoedema.

Dr Parmjot Bains, Managing Director and CEO of ImpediMed stated "Coinciding with the start of Breast Cancer Awareness month, the inclusion of BIS as an example of high-quality care in the NABPC accreditation standards continues to support the use of our technology as a standard of care to support survivorship for breast cancer patients. The authors of the NABPC standards are leaders in US breast cancer care and these standards are highly influential for clinicians and their facilities as well as patients."

**Approved for release by Managing Director and CEO, Dr Parmjot Bains**

For more information, contact:

P: +61 7 3860 3700

E: [investorrelations@impedimed.com](mailto:investorrelations@impedimed.com)

W: [impedimed.com](http://impedimed.com)

---

<sup>1</sup> [https://accreditation.facs.org/accreditationdocuments/NABPC/Standards/Optimal\\_Resources\\_for\\_Breast\\_Care\\_2024.pdf](https://accreditation.facs.org/accreditationdocuments/NABPC/Standards/Optimal_Resources_for_Breast_Care_2024.pdf)



### **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS). ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including lymphoedema and is sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

### **About SOZO Digital Health Platform**

SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).